Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Jul 26, 2020 2:05pm
317 Views
Post# 31320960

RE:Any thoughts on Proxy Voting for Proposals 3 & 5

RE:Any thoughts on Proxy Voting for Proposals 3 & 5
aussyspitz wrote: If the share price was currently sitting above a $1 USD I probably wouldn't have an issue voting FOR all their propsals straight down.  Unfortunately it is not above a $1 and as a result  I'm finding myself very reluctant to vote for Proposal 3:  Expanded RSU's and Proposal 5: Increased Stock Options. Anyone else having this same dilema and any thoughts/discussion on the matter?  



Peculiar timing Aussy.  I have just spent a couple of hours looking into this.  20% of the existing shares to be awarded under the incentive plan seems excessive, twice as much as the 10% normally provided by other companies, and also more than the Board would normally expect.  From the information circular:  
 
"the aggregate number of Shares reserved for issuance under RSUs to Insiders
(as a group), together with all other Security Based Compensation
Arrangements, at any point in time may not exceed 10% of the issued and
outstanding Shares, unless the Corporation has first obtained disinterested
shareholder approval of this Plan pursuant to the policies of the Exchange;"
 
However, upon scratching deeper, I see that the company has had a 20% policy for a considerable time, and the increase in RSUs reflects this past practice based on the new post-bought-deal share count. Also, there are only a couple of million shares remaining in the existing plan that have not yet been awarded. Perhaps, not as bad as it originally appeared. 
 
 I suspect that a stock award announcement will be made shortly after the AGM.  Awards typically follow achievements, and the successful completion of Phase 2 certainly was a major event.  Also, (my observation) options are normally granted near end FY and/or following  a positive development. Also, the corporation has stated that it grants awards annually as a matter of policy, and it has yet not done so this year.
 
This occurence (if it happens) likely won't sit well with many shareholders.
Bullboard Posts